

4729:1-6-01

Definitions - Consult Agreements.

(A) "Communication between a pharmacist and physician acting under a consult agreement", as used in division (B)(6) of section 4729.39 of the Revised Code, means any of the following:

(1) Electronic mail that confirms delivery;

(2) Interoperable electronic medical records system;

(3) Facsimile that confirms delivery;

(4) Electronic prescribing system;

(5) Electronic pharmacy record system;

(6) Documented verbal communication; or

(7) Any other method of documented notification as outlined in the consult agreement between the pharmacist and physician.

(B) "Comorbid disease", as used in division (B)(3)(a) of section 4729.39 of the Revised Code, means an additional disease that co-occurs with a primary disease. A comorbid disease may be related to or occur independently of the primary disease.

(C) "Consult agreement" means an agreement that has been entered into pursuant to section 4729.39 of the Revised Code.

(D) "Primary disease", as used in division (B)(3)(a) of section 4729.39 of the Revised Code, means a disease that arises spontaneously and is not associated with or caused by a previous disease, injury, or event, but that may lead to a comorbid disease.

(E) "Training and experience related to the particular diagnosis for which drug therapy is prescribed", as used in division (A)(3) of section 4729.39 of the Revised Code, means an Ohio licensed pharmacist whose license is in good standing and who meets the training and experience criteria specified in paragraph (A)(1)(k) of rule 4729:1-6-02 of the Administrative Code.

(F) "Written notice", as used in division (B)(2)(b) of section 4729.39 of the Revised Code, means one of the following methods that is capable of confirming delivery of the required written notice:

(1) Electronic mail;

(2) Interoperable electronic medical records system;

(3) Facsimile;

(4) Electronic prescribing system;

(5) Electronic pharmacy record system;

(6) Any other method in writing that provides notice in a timely manner; or

(7) Any other method of notification as outlined in the consult agreement that might reasonably be expected to allow for the confirmed transmission of the written notification required.

(G) "Institutional facility" has the same meaning as defined in rule 4729-17-01 of the Administrative Code.

(H) "Communicated" as used in division (B)(4) of section 4729.39, means consent shall be obtained from each individual patient participating in a consult agreement. With the exception of inpatient management of patient care at an institutional facility as defined in rule 4729-17-01 of the Administrative Code, consent shall be obtained prior to a pharmacist managing a patient's drug therapy and shall communicate all of the following:

(1) A pharmacist may be utilized in the management of the patient's care; and

(2) The patient's or an individual authorized to act on behalf of a patient's right to elect to participate in and withdraw from the consult agreement.

(I) Consent as required in paragraph (H) of this rule may be obtained as a part of the patient's initial consent to treatment.

(J) "Managing pharmacist" means a pharmacist managing a patient's drug therapy pursuant to a consult agreement.

Replaces: 4729-29-01
Effective: 10/01/2017
Five Year Review (FYR) Dates: 10/01/2020

CERTIFIED ELECTRONICALLY

Certification

08/07/2017

Date

Promulgated Under: 119.03
Statutory Authority: 4729.26, 4729.39, 3719.28
Rule Amplifies: 4729.01, 4729.39
Prior Effective Dates: 8/18/2016